The launch of the first drugs to inhibit the cancer-related protein KRAS was a milestone moment in oncology, but their efficacy wanes over time and tumours can develop res
Astellas has become the latest big pharma to pledge big bucks to a smaller company working on protein degraders, paying $35 million upfront to partner with US start-up Cul
One of the most compelling things about artificial intelligence chat technologies like ChatGPT and AIChat is their ability to generate human-like responses - but that may
In amongst the big clinical trial readouts at ASCO, a new research project made its official debut with the ambitious goal of mapping cancer cells’ interactions with their
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl